Last reviewed · How we verify

NCT07509775

Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring System

Recruiting now Last updated 9 April 2026
What this trial tests

trial in Ankylosing Spondylitis (AS) in 210 participants. Currently enrolling.

Timeline
19 January 2026
Primary endpoint
31 December 2027
30 June 2028

Quick facts

Lead sponsorChina-Japan Friendship Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment210
Start date19 January 2026
Primary completion31 December 2027
Estimated completion30 June 2028
Sites1 location across China

Conditions studied

Sponsor

China-Japan Friendship Hospital

Who can join

Adults 18 to 75, any sex, with Ankylosing Spondylitis (AS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multicentre, ambidirectional, observational cohort study. The ambidirectional design incorporates both the collection of retrospective data from the three years prior to enrolment, and a prospective follow-up period of up to two years. The study is designed to evaluate the long-term effects of Integrated Medicine on radiographic progression in patients diagnosed with Ankylosing spondylitis (AS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ankylosing Spondylitis (AS)

Currently open trials in the same condition.

Other China-Japan Friendship Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07509775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing